UPDATE: UBS Upgrades AbbVie To Buy, Lowers Target To $79 As Firm Notes Co's 'acquisition of AGN leads to a NEWCO generating $20B+ of annual free cash flow growing to a highly compelling, 9% FCF yield in '23E (year of Humira's US patent expiry)'

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!